BioNTech Posts Quarterly Profit but Nine-Month Loss as It Buys FDA Speed for $205 Million
Published on 11/14/2026 at 20:40 | Editorial boerse-global.de
BioNTech closed the third quarter of 2026 with revenue of €1.29 billion and an IFRS net profit of €184.5 million, yet the same set of figures, released on 3 November, shows the company still underwater on a cumulative basis. For the first nine months of the year, the German biotech reported an IFRS net loss of €1.17 billion, with nine-month revenue of €1.51 billion. A single profitable quarter, in other words, has not been enough to pull the year-to-date result into the black.
The Mainz-based group filed the numbers and its operating report with the US Securities and Exchange Commission on Form 6-K. Alongside the income statement, it disclosed cash, cash equivalents and securities investments totaling €16.2 billion — a cushion that includes not only immediately available funds but also holdings in marketable securities.
A $205 Million Voucher for the Oncology Pipeline
On Tuesday, BioNTech struck an agreement with Scholar Rock to acquire a Priority Review Voucher from the US Food and Drug Administration. The price is $205 million, payable entirely in cash. Closing is subject to customary conditions, among them antitrust clearance under the Hart-Scott-Rodino process.
Should investors sell immediately? Or is it worth buying BioNTech?
According to the company, the voucher will support a future marketing application for a late-stage oncology asset. BioNTech has not named the candidate in question. Handelsblatt linked the planned outlay to the company's cost-reduction program.
Guidance Raised at the Bottom End
In early November, BioNTech lifted the midpoint of its full-year 2026 revenue forecast. The range now stands at €1.7 billion to €1.9 billion, up from the previous €1.6 billion to €1.9 billion. The revision therefore applies to the lower bound of the guidance. Forecasts for adjusted research and development spending and for adjusted selling and general administrative costs were left untouched.
Roche to Carry a Program's Costs From 2027
Also in early November, BioNTech said it had exercised an option within its collaboration with Roche/Genentech. As a result, future research and development costs for the program concerned are to be allocated in principle to Roche/Genentech from 1 January 2027. Should development and commercialization succeed, BioNTech could receive royalty payments. The ongoing pancreatic cancer study is to continue as planned.
The two announcements — a regulatory shortcut bought for cash and a shifting of development costs onto a partner — sketch out a company working both sides of the ledger at once: paying to accelerate the late-stage pipeline while arranging for others to shoulder part of the burden. Whether that combination narrows the gap left by nine months of losses is the question the fourth quarter will have to answer.
Ad
BioNTech Stock: New Analysis - 14 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
